CGM represents a fundamental therapeutic tool in type 1 diabetes since it allows to address the potential issues related to the "timing" of insulin administered at meals, the insulin-carbohydrate ratio (and more generally, the influence of other nutrients including proteins and fats) and the management of night period. This evidence concerns the gene INS and type 1 diabetes mellitus.